AI-Based Drug Discovery Tools Ver 1.0

AI-Based Drug Discovery Tools

Welcome to our latest edition, where we highlight transformative developments at the intersection of artificial intelligence and drug discovery. This issue showcases innovative tools and platforms revolutionizing research, enhancing precision medicine, and speeding up the creation of new therapies. We delve into AI-powered search engines, digital twins of cells, quantum physics-based drug discovery, and advanced bioinformatics platforms, presenting the most promising advancements shaping the future of healthcare.

Join us as we explore these groundbreaking technologies and meet the leaders driving these innovations forward. Stay informed about the latest breakthroughs and collaborations pushing the boundaries of biomedical research. Let's embark on this journey of discovery together!

Consensus is changing the landscape of research with its AI-driven search engine, now enhanced by Centaur Lab's data annotations. This tool handles various data types, including:

• Text: Unstructured clinical notes, scientific texts, chatbots, etc.

• Audio: Heart, lung, and artery auscultation, among others.

• Images: Ultrasounds, external images, X-rays, etc.

• Video: Surgeries, clinical sessions, etc.

• Wave: EEG, ECG, and more.

Eric Olson, CEO and co-founder, describes Consensus as “like Google Scholar + ChatGPT.” He emphasizes making peer-reviewed research easily accessible, allowing even those outside academia to sound knowledgeable.

Eric attributes his leadership principles to lessons from football:

• Ignore the noise.

• Control what you can control.

• Everybody loves a good story.

• Authentic leadership is the only leadership.

In 2024, Consensus launched Consensus GPT: The Leading GPT for Research, providing access to over 200 million academic papers via ChatGPT. This tool simplifies discovering research papers, extracting key insights, and drafting academically rigorous content. They also introduced the Consensus Copilot, which:

• Executes specific research tasks, like drafting a literature review outline.

• Explains complex concepts in layman’s terms.

• Answers questions with flexible formatting and accurate citations.

Centaur Lab has raised $16M.

PipeBio, established in Denmark in 2020, offers a cloud-based bioinformatics platform for biologics discovery. It allows wet lab scientists to analyze antibody and peptide sequences effortlessly, offering tools for:

• Sequence storage and powerful querying.

• Configuring workflows and automation via API.

• A secure cloud platform.

Founded by Jannick Bendtsen and Owen Bodley, PipeBio's team combines diverse backgrounds from wet-lab biology to computer engineering.

In April 2024, PipeBio integrated Bruker Cellular Analysis Beacon® data, demonstrating the efficient recovery of high-quality variable sequences from pre-screened cells. This sequence and assay data can be analyzed using the PipeBio platform.

Cradle Bio from the Netherlands, emerged in 2022 and uses generative AI for protein engineering. Co-founded by Stef Van Grieken and Elise de Reus, Cradle has raised $33M and partnered with Ginkgo in February 2024 to enhance protein engineering using generative ML models. They presented a case study in March 2024 showing a 4X faster design of P450 enzymes.

DeepLife, a French startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, is developing a SaaS platform for digital twins of cells. This platform combines DL algorithms on multi-omics sequencing data with advanced cell engineering tools. In November 2023, they collaborated with the University of Zurich to create digital twins of cystinosis-affected cells for enhanced drug discovery.

DeepLife has raised $6M.

New Atlantis in the US focuses on marine biodiversity and metagenomics. Co-founded by Gordon Gould, they aim to study marine microorganisms' genomes using high-throughput DNA sequencing. Gould recently attended the “Our Ocean Conference” in Athens.

Intelligent OMICS (Intellomx), a UK startup, employs the I3 methodology to discover novel biological targets and predict pre-clinical toxicity effects, reducing development costs and animal trials. In September 2023, they announced a collaboration with Janssen to explore new targets for hematological cancers.

Pathos, a clinical-stage biotech founded in 2020 by Eric Lefkofsky, uses AI to enhance precision medicine. They completed the acquisition of Rain Oncology Inc. in January 2024. Pathos has raised $40M.

Eleven Therapeutics, founded in 2020 in Israel, leverages synthetic chemistry and AI to enhance mRNA therapeutics. They use TERÅ beads to boost RNA molecule performance. They’ve partnered with Novo Nordisk and Dong-A ST for RNA-based gene therapy development. Eleven Therapeutics has raised $26.3M.

Glass Health, founded in 2021 in the US by Dereck Paul and Graham Ramsey, connects a large language model to clinical guidelines for AI-powered clinical decision support. They raised $7M and joined the Google for Startups AI-First Accelerator in April 2024.

Aqemia, a French startup, uses quantum physics and AI for drug discovery. They extended their collaboration with Servier and secured a $140M multi-year agreement with Sanofi. Aqemia raised €30M in January 2024.

Clarivate offers the Cortellis Drug Discovery Intelligence™ platform to de-risk and accelerate drug discovery. In 2023, they partnered with VeriSIM to enhance drug development. Recently, they announced an acquisition agreement with MotionHall to integrate AI solutions into their platform.

That’s a Wrap!

Thank you for joining us in exploring the latest advancements in AI-based drug discovery. We hope you found this edition insightful and inspiring. Stay tuned for our next newsletter, where we'll continue to bring you the cutting-edge developments and trends in the world of AI and biomedical research. Exciting updates await you, so don’t miss out!